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TO THE EDITOR
Chemotherapy-induced hair follicle
(HF) dystrophy and alopecia are major
unresolved problems in clinical onco-
logy (Wang et al., 2006; Bodo´ et al.,
2007; Lemieux et al., 2007). Although
the study of cyclophosphamide-
induced alopecia in mice has provided
important pointers to potentially
useful agents that might deserve clinical
testing and has allowed us to dissect
some of the basic pathobiological me-
chanisms (Paus et al., 1994, 1996; Schilli
et al., 1998; Botchkarev et al., 2000;
Ohnemus et al., 2004; Sredni et al.,
2004; Hendrix et al., 2005), the—as yet
unmet—challenge is to develop a con-
vincing preclinical assay system that
allows one to predict how chemother-
apy-treated human scalp HFs respond to
the various candidate alopecia protec-
tants that have surfaced from rodent
studies.
Recently, we established a human
in vitro model for studying chemother-
apy-induced HF dystrophy (Bodo´ et al.,
2007), which reliably re-produces the
HF damage seen in vivo. In this assay,
cyclophosphamide, a classical cyto-
static agent that frequently causes
chemotherapy-induced alopecia in
clinical medicine (Braun-Falco, 1961)
is replaced by one of its active toxic
metabolites normally generated in vivo,
4-hydroperoxycyclophosphamide (4-
HC). Using this human model we could
show that 4-HC profoundly inhibits hair
shaft elongation, matrix keratinocyte
proliferation, induces massive apopto-
sis of matrix keratinocytes and melanin
clumping (Bodo´ et al., 2007).
Chemotherapy-induced HF damage
follows two distinct pathways: dys-
trophic anagen and dystrophic catagen
(Paus et al., 1994; Hendrix et al., 2005).
During the dystrophic anagen pathway,
the hair shaft is shed, and the follicle
undergoes an incomplete ‘‘primary
recovery’’ during an (paradoxically
prolonged!) anagen phase. This is fol-
lowed by a retarded ‘‘secondary recov-
ery’’ during which a normal hair shaft is
generated in the subsequent anagen
phase. By contrast, HFs that undergo
the dystrophic catagen (DC) pathway
(for example, in response to a higher
dose of chemotherapy) immediately
enter into a dystrophic catagen stage,
followed by an abnormally shortened
telogen phase, and thus rapidly enter
into secondary recovery by premature
induction of a new anagen phase.
Therefore, even though it is clinically
associated with the most dramatic
effluvium/alopecia, the DC pathway
leads to the fastest, complete HF
recovery (Paus et al., 1994; Hendrix
et al., 2005).
In mice, in vivo, topical application
of steroid hormones (dexamethasone,
calcitriols, or 17-b-estradiol (E2)) before
and after systemic cyclophosphamide
administration potently promotes the
DC pathway. Thus, these steroid hor-
mones greatly enhance the initial
alopecia, but maximally accelerate the
regrowth of normally pigmented hair
shafts as HF ‘‘secondary recovery’’ is
optimally enhanced (Paus et al., 1994;
Schilli et al., 1998; Ohnemus et al.,
2004).
Therefore, we were interested in
studying how E2 or a combination of
E2 with glucocorticosteroids would
affect 4-HC-induced human scalp HF
damage in our new human in vitro
model (Bodo´ et al., 2007), and whether
there are any indications where these
steroid hormones, alone or in combina-
tion, promote the DC pathway. We
purposely selected E2 and a combina-
tion with prednisolone (P) for further
study, as the topical application of both
has a long tradition of clinical applica-
tion in central European dermatology
for hair loss management (Abadjieva,
2000; Wu¨stner and Orfanos, 1974).
Due to the extremely limited number
of available human scalp HFs, we
opted for testing of one E2 and P
concentration, and selected 107 M
after selected (Kanda and Watanabe,
2004).
Anagen VI HFs were isolated from
normal human scalp skin from healthy
female patients undergoing routine
face-lift surgery (obtained after ethics
committee approval and written con-
sent from patient, adhering to Helsinki
guidelines) as described (Philpott et al.,
1990). We received HFs (10–18 HFs per
Abbreviations: 4-HC, 4-hydroperoxicyclophosphamide; DC, dystrophic catagen pathway; E2, 17-b
estradiol; HF, hair follicle; P, prednisolone
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group) from female patients (all 50-year
old). Isolated HFs were maintained in
supplemented, serum-free Williams’
E medium and treated with 4-HC
(30 mM) as described (Bodo´ et al.,
2007). Before the first 4-HC treatment,
follicles were incubated with E2/P (both
107 M) or their combination for 12
hours and then co-cultured with or
without (vehicle) 4-HC for further 3
days. After cryoembedding of cultured
HFs, 6-mm thick cryostat sections
were prepared for histology. HF mor-
phology and HF cycle staging were
performed on Masson–Fontana stained
cryosections as described (Bodo´ et al.,
2007).
First, we assessed the impact of E2/P
on the 4-HC-induced inhibition of hu-
man hair shaft elongation in vitro. Hair
shaft length was measured every
second day on each individual HF. As
expected (Bodo´ et al., 2007), 4-HC
significantly inhibited hair shaft elonga-
tion (Figure 1a). As reported before
(Conrad et al., 2004), E2 alone also
caused a significant reduction of hair
shaft growth (Figure 1a). E2 further
enhanced 4-HC-induced hair shaft in-
hibition. This inhibitory effect of E2 was
further augmented by P, whereas P
alone did not alter hair shaft elongation
significantly (Figure 1a).
Next, we investigated whether this
inhibition was accompanied by altered
HF cycling in vitro, as one of the key
abnormalities of cyclophosphamide-in-
duced alopecia in vivo is premature
anagen VI termination and massive,
apoptosis-driven HF regression (cata-
gen), both in humans (Braun-Falco,
1961) and in mice (Paus et al., 1994).
Although approximately 80% of vehi-
cle-treated follicles still displayed ana-
gen VI morphology, 4-HC treatment
reduced this number to 10%, as ex-
pected (Bodo´ et al., 2007). Interest-
ingly, this premature catagen induction
by 4-HC was further enhanced by E2
and P co-administration (Figure 1b).
After combined treatment with E2 and
P, HFs even showed late catagen
morphology (Figure 1b), which is ob-
served only very rarely in sponta-
neously regressing human scalp HFs of
the Philpott assay. This clearly indicates
that E2 and P, by themselves, are potent
catagen inducers in organ-cultured
human anagen HFs, and further
promote their 4-HC-driven premature
catagen transformation.
The 4-HC-induced hair cycle
changes were associated with the ex-
pected abnormal melanin production,
transfer, and deposition, as an indicator
of substantial HF dystrophy (Tobin
et al., 1998; Hendrix et al., 2005; Bodo´
et al., 2007). However, we failed to
observe a significant, well-reproducible
modulatory effect on melanin clump-
ing/transfer by E2/P in this assay. E2/P
increased significant melanin clumping
only in the HFs of a single patient,
indicating a greater level of HF dystro-
phy by E2/P.
Finally, we tested whether the hair
shaft elongation-inhibitory and cata-
gen-promoting effects of E2 were asso-
ciated with a significant alteration in
the number of the proliferating and/or
apoptotic matrix keratinocytes. For the
simultaneous detection of proliferating
and apoptotic keratinocytes, the Ki-67/
TUNEL double staining was used (Bodo´
et al., 2007). As shown in Figures 1c
and d, quantitative immunohistomor-
phometry revealed that E2 alone as well
as E2/P, but not P alone, significantly
inhibited human hair matrix keratino-
cyte proliferation and enhanced their
entry into apoptosis. Furthermore,
co-administration of E2 or E2/P with
4-HC augmented the proliferation–inhi-
bitory effect of 4-HC on human hair
matrix keratinocytes. These data are in
line with the hair shaft elongation,
catagen induction, and HF dystrophy
observations summarized above.
Although this limited pilot study
calls for follow-up testing with more
HFs from a larger number of individuals
of both sexes, as well as for full
dose–response assays, and reflects
a systemic mode of test agent applica-
tion, not a topical one, it already invites
to the following clinically important
conclusions:
(1) Steroid hormones that are fre-
quently employed in clinical
dermatology, namely E2 and P,
exert profound modulatory effects
on human scalp HF growth,
cycling, and hair shaft formation.
(2) The tested dose of E2 and P (107 M)
clearly promotes the DC pathway
of response to chemotherapy-
induced HF damage/dystrophy in
normal human scalp HFs.
(3) This is the first evidence from a
physiologically relevant human
preclinical test system, which sug-
gests that our corresponding ob-
servations and concepts in the
murine system in vivo (Paus
et al., 1994; Ohnemus et al.,
2004; Hendrix et al., 2005), with
which the current ones are well in
line, are indeed relevant to the
human system.
(4) The combined administration of
E2 and P tends to further enhance
the dystrophic catagen response
pathway to chemotherapy-in-
duced HF damage.
Although the underlying molecular
mechanisms are widely unknown, one
could speculate which molecular path-
ways may be involved here. As re-
viewed by Ohnemus et al. (2006), HFs
serve as estrogen target tissue and
estrogens reportedly alter gene expres-
sion of several hair cycle-relevant genes
or signaling pathway members, that is,
mitogen-activated protein kinase path-
way, transforming growth factor/bone
morphogenetic protein family, which
may be involved in further catagen and
apoptosis induction.
Using the C57BL/6 mouse model for
the study of chemotherapy-induced
alopecia, we had found that topically
applied steroid hormones, such as
dexamethasone, calcitriol, and E2 that
promote the ‘‘dystrophic catagen’’
pathway, in vivo, induce a more
pronounced, massive initial alopecia,
followed by a significantly accelerated
regrowth of normally pigmented hair
shafts (Paus et al., 1994, 1996;
Ohnemus et al., 2004; Hendrix et al.,
2005). As the tested steroid hormones
also stimulated the ‘‘dystrophic
catagen’’ pathway in organ-cultured
human scalp HFs, it is reasonable to
expect a similar clinical outcome
after application of these test agents
to human scalp in vivo: If similarly
high doses of E2 and/or E2/P can be
achieved after topical application as
have been administered in the current
organ culture system, one would
have to predict that topical E2 and/or
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E2/P to chemotherapy-treated patients
shortly before and after chemotherapy
will—just as in mice—initially enhance
the degree and velocity of hair loss.
Subsequently, however, this treatment
should greatly accelerate the regrowth
of normally pigmented hair shafts, at
least when cytostatic agents are
employed that are comparable to
cyclophosphamide. Naturally, only
clinical trials will now be able to
ascertain whether or not these preclini-
cal pilot data are transferable to the
in vivo situation. If this turns out to
be the case, the central question will
be: Can physicians really convince
their patients who are threatened
by the negative psychosocial implica-
tions of cyclophosphamide-induced
alopecia (Wang et al., 2006; Lemieux
et al., 2007) that it is a good strategy
to promote the hair loss so as to
allow for maximally accelerated HF
recovery, that is, to even enhance the
initial alopecia so as to, then, greatly
shorten the time until normal hair
regrowth?
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Figure 1. 17-b Estradiol promotes the dystrophic catagen pathway of human scalp hair follicles. (a) The elongation of treated and vehicle (100%) groups
were compared at the end of the culture period. (b) HF cycle staging was carried out according to previously defined morphological criteria (Paus and
Cotsarelis, 1999), and the percentage of HFs in anagen, early, mid, or late catagen was determined. (c) Numbers of the Ki-67þ (proliferative, red) and
TUNELþ (apoptotic, green) cells were counted in the region indicated and normalized to the number of DAPIþ cells (all cell nuclei). (d) Representative
images of vehicle, 4-HC, and E2þ 4-HC-treated follicles stained with Ki-67/TUNEL. DP, dermal papilla; MK, matrix keratinocytes. Original magnification
200. Mean±s.e.m., *Po0.05, **Po0.01 (Mann–Whitney U-test), n¼10–18 HF per group, bar¼ 50mm.
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TO THE EDITOR
Nonne–Milroy disease (OMIM x153100)
is an autosomal dominant form of
primary lymphedema caused by muta-
tions in the FMS-like tyrosine kinase 4
(FLT4) gene, encoding the vascular
endothelial growth factor receptor 3
(VEGFR3) involved in development of
the lymphatic system (Iljin et al., 2001;
Ferrell, 2002; Saaristo et al., 2002).
Mutations in FLT4 exhibit strongly
varying penetrance, with women more
often affected (Ferrell, 2002; Evans
et al., 2003). In 96% of cases, the
lymphedema is congenital (Ferrell,
2002). Almost all FLT4 mutations in
Nonne–Milroy disease are heterozygous
missense mutations affecting the intra-
cellular tyrosine kinase domains. Mu-
tant receptors are more stable than their
wild-type (WT) counterpart, exhibiting
an approximately 40% longer half-life
(Karkkainen et al., 2001; Ferrell, 2002).
This results in accumulation of the
mutant receptor on the cell surface
and ligand capture, explaining the
dominant character of FLT4 mutations
(Karkkainen et al., 2000). It might
Abbreviations: ERK, extracellular signal-regulated kinase; FLT4, FMS-like tyrosine kinase 4; HUVEC,
human umbilical vein endothelial cells; VEGF-C, vascular endothelial growth factor C; VEGFR, vascular
endothelial growth factor receptor; WT, wild type
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